Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01865799 · ClinicalTrials.gov registry record
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
A clinical trial of Pre-exposure Prophylaxis for Prevention of HIV Infection, sponsored by Gilead Sciences.
- Completed
- Registry status
- 64,186
- Enrollment target
- 1
- Study location
NCT01865799 is a study of Pre-exposure Prophylaxis for Prevention of HIV Infection that has completed, run by Gilead Sciences. The registered enrollment target is 64,186 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01865799, a study of Pre-exposure Prophylaxis for Prevention of HIV Infection, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 64,186 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, 3-year observational study to describe drug utilization in uninfected individuals (UIs) who initiate emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication. An electronic source of pharmacy/medical encounter information will be used to assess the demographics and other characteristics of the subjects prescribed FTC/TDF or its components in a prospective fashion. The data provider will supply all the de-identified information regarding each visit/interaction that the subject has had with the health system and all the diagnoses and medications that the UI has had prospectively and retrospectively for the length of time captured by the source selected. 200 physicians who prescribe FTC/TDF for a PrEP indication will be sampled from the same source.
Conditions Studied
Study Locations (1)
California
- Gilead Sciences, Inc. - Foster City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64,186 participants |
| Start Date | 2013-04-22 |
| Est. Completion | 2018-01-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01865799
The ClinicalTrials.gov registry entry for NCT01865799 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 64,186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pre-exposure Prophylaxis for Prevention of HIV Infection appearing as the primary indexed condition, and to 0 interventions.
NCT01865799 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01865799 about?
NCT01865799 is a clinical study titled "A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA". This is a prospective, 3-year observational study to describe drug utilization in uninfected individuals (UIs) who initiate emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication. An electronic source of pharmacy/medical encounter informa...
What is the current status of trial NCT01865799?
This trial is currently completed. The enrollment target is 64,186 participants. The study started on 2013-04-22. Estimated completion is 2018-01-22.
What conditions does trial NCT01865799 study?
This clinical trial studies the following conditions: Pre-exposure Prophylaxis for Prevention of HIV Infection.
Who is sponsoring clinical trial NCT01865799?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01865799 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.